Larvol Delta - ALTITUDEAD-Cost-savings-using-a-pTau217-screening-assay-in-an-ongoing-Phase-2-study-of-sabirnetug-in-early-Alzheimers-disease

sabirnetug IV (ACU193 IV) - Acumen Pharma

https://www.globenewswire.com/news-release/2025/07/28/3122403/0/en/Acumen-Pharmaceuticals-Presents-Studies-Showing-the-Utility-of-a-pTau217-Assay-in-Screening-for-a-Phase-2-Alzheimer-s-Disease-Trial-and-Validates-Sabirnetug-Oligomer-Selectivity-at.html

Jul 28, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next